FOLFIRI标准化疗方案联合不同剂量贝伐单抗治疗对晚期转移性结直肠癌近、远期疗效及毒副反应分析

Effect of FOLFIRI Standard Chemotherapy Regimen Combined with Different Doses of Bevacizumab on the Short-term and Long-term Efficacy and Side Effects of Patients with Advanced Metastatic Colorectal Cancer

目的探讨FOLFIRI标准化疗方案联合不同剂量贝伐单抗治疗对晚期转移性结直肠癌患者近、远期疗效及毒副反应。方法收集2019年1月~2021年12月在本院进行治疗的92例晚期转移性结直肠癌患者的临床资料。2组均予FOLFIRI标准化疗方案联合贝伐单抗治疗,根据贝伐单抗剂量分为观察组(7.5mg/kg贝伐单抗)及对照组(5mg/kg贝伐单抗)。对比2组近、远期疗效及毒副反应总发生率。结果(1)观察组疾病控制率81.25%明显高于对照组61.36%(P<0.05)。(2)2组毒副反应发生率对比无明显差异(P>0.05)。(3)对照组1年存活率18.18%明显低于观察组37.50%(P<0.05);经过log-rank检验显示观察组PFS、OS均显著长于对照组(P<0.05)。结论7.5mg/kg贝伐单抗治疗晚期转移性结直肠患者的临床疗效要明显高于5mg/kg贝伐单抗治疗,有利于延长患者生存期,安全性较高。

Objective To explore the effect of FOLFIRI standard chemotherapy regimen combined with different doses of bevacizumab on the short-term and long-term efficacy and side effects of patients with advanced metastatic colorectal cancer.Methods The clinical data of 92 patients with advanced metastatic colorectal cancer who were treated in our hospital from January 2019 to December 2021 were collected.Both groups were treated with FOLFIRI standard chemotherapy regimen combined with bevacizumab.According to the dose of bevacizumab,they were divided into observation group(7.5mg/kg bevacizumab)and control group(5mg/kg bevacizumab).The short-term and long-term efficacy of the two groups were compared,and the total incidence of tumor markers and side effects before and after treatment.Results(1)The disease control rate of the observation group was 81.25%,which was significantly higher than that of the control group 61.36%(P<0.05).(2)There was no significant difference in the incidence of toxic side effects between the two groups(P>0.05).(3)The 1-year survival rate of the control group was 18.18%significantly lower than that of the observation group 37.50%(P<0.05).The log-rank test showed that PFS and OS in the observation group were significantly longer than those in the control group(P<0.05).Conclusion The clinical efficacy of 7.5 mg/kg bevacizumab in the treatment of patients with advanced metastatic colorectal is significantly higher than that of 5 mg/kg bevacizumab,which is beneficial to hinder the progression of the tumor,prolong the survival period of the patient,and has high safety.It has important clinical use value.